# SGLT2 Inhibitor TrEatment iN Patients Awaiting cOronary arTery bYpass Surgery to Reduce Post-opErative AF

Study · id `cardio:ct-nct05852704` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05852704](<https://clinicaltrials.gov/study/NCT05852704>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05852704

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 800 participants.

## Technical summary

Registry record NCT05852704. Randomized; quadruple masking; primary purpose prevention. Start 2024-04-04 (actual); primary completion 2027-12-04 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 800 participants (planned count; ClinicalTrials.gov record NCT05852704, source copy `cardio:ctgov-nct05852704-2025-04-08`, retrieved 2026-10-26)
- Started: 2024-04-04 (actual) (ClinicalTrials.gov record NCT05852704, source copy `cardio:ctgov-nct05852704-2025-04-08`, retrieved 2026-10-26)
- Primary completion: 2027-12-04 (anticipated) (ClinicalTrials.gov record NCT05852704, source copy `cardio:ctgov-nct05852704-2025-04-08`, retrieved 2026-10-26)
- Completion: 2028-12-04 (anticipated) (ClinicalTrials.gov record NCT05852704, source copy `cardio:ctgov-nct05852704-2025-04-08`, retrieved 2026-10-26)
- Countries: Czechia; Denmark; Sweden (ClinicalTrials.gov record NCT05852704, source copy `cardio:ctgov-nct05852704-2025-04-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05852704-2025-04-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: SGLT2 Inhibitor TrEatment iN Patients Awaiting cOronary arTery bYpass Surgery to Reduce Post-opErative AF
- Acronym: STENOTYPE
- Condition: Chronic Coronary Syndrome
- Condition: Atrial Fibrillation
- Intervention (Drug): Dapagliflozin 10mg Tab
- Intervention (Drug): Placebo Tab
- Lead sponsor: Region Örebro County
- Lead sponsor class: OTHER
- Collaborator: Odense University Hospital
- Collaborator class: OTHER
- Collaborator: Aarhus University Hospital
- Collaborator class: OTHER
- Collaborator: Örebro University, Sweden
- Collaborator class: OTHER
- Collaborator: Sahlgrenska University Hospital
- Collaborator class: OTHER
- Collaborator: Göteborg University
- Collaborator class: OTHER
- Collaborator: University of Leeds
- Collaborator class: OTHER
- Collaborator: Skane University Hospital
- Collaborator class: OTHER
- Collaborator: London School of Hygiene and Tropical Medicine
- Collaborator class: OTHER
- Collaborator: St. Anne's University Hospital Brno, Czech Republic
- Collaborator class: OTHER
- Collaborator: Mount Sinai Hospital, New York
- Collaborator class: OTHER
- Collaborator: Icahn School of Medicine at Mount Sinai
- Collaborator class: OTHER
- Collaborator: University Hospital, Linkoeping
- Collaborator class: OTHER
- Collaborator: Copenhagen University Hospital, Rigshospitalet
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Dapagliflozin (`cardio:dapagliflozin`)
- Registry intervention is a member of this class by a sourced record link: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)

## Registry records

Records a program assembled from a public registry; no person wrote or checked them. They are counted here, not listed: the JSON record of this page lists each one in its relationships.

- 13 registry organizations

## Provenance

Content hash: 0bc44b0a39f66cca6ae17d5be45651bc284f340fa80f4d59ab4460d24db8bd8b
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
